2,168 results on '"Idrus, Amirah Al"'
Search Results
2. Novartis veteran Barth takes the helm at autoimmune biotech MiroBio
3. FDA hits pause on Protagonist's blood cancer med after mouse study turns up skin tumors
4. China's IASO nets $108M to advance cell therapies, antibodies for cancer, autoimmune disease
5. Tyra Biosciences banks $173M to bring cancer resistance programs into clinic
6. AzurRx boosts GI pipeline through First Wave buyout worth up to $229M
7. AltruBio snags a CMO after pivot from oncology to immunology
8. Mammoth Bio scores $195M top-up to supercharge CRISPR diagnostics, medicines
9. Journey Colab scores $12M to move psychedelics-based addiction treatment into clinic
10. Laronde banks $440M to ramp up RNA-based meds that could turn cells into protein factories
11. Bone Therapeutics' lead program falls short in knee osteoarthritis
12. Parallel Bio is putting the immune system in a dish to improve drug discovery
13. Humane Genomics is 3D-printing oncolytic viruses to treat rare cancers
14. NovaRock takes stomach cancer program global through Flame BioSciences deal worth up to $640M
15. Lilly doubles down on protein degradation, inking $35M deal with Lycia and promising $1.6B more
16. Roche's gene therapy plans take Shape with $3B-plus biobucks deal
17. Marinus tees up phase 3 for rare epilepsy med that slashes seizures in mid-stage trial
18. Jnana nets $50M to push newly unveiled PKU program, expand into more hard-to-drug targets
19. Psychedelics are getting closer to approval, but the market may not be ready
20. Beckley Psytech bags $80M to fuel psychedelics for depression, debilitating headaches
21. FDA veteran and outspoken expert Unger retires as the agency finds itself at a crossroads
22. Keeping up with COVID-19: Atea reveals trial amendments, new data
23. GentiBio banks $157M to fuel Treg treatment for Type 1 diabetes
24. Takeda takes the lead on Finch-partnered microbiome drug for IBD
25. Epizyme CEO Bazemore passes the baton as company looks to 'next phase of growth'
26. Sonoma Bio bags $265M to rev up cell therapies for arthritis, diabetes
27. Alector bolsters 'immuno-neurology' approach--and GSK's $700M bet--with early phase 2 data
28. Nuvalent pulls off $166M IPO to move resistance-beating lung cancer programs into the clinic
29. Arena taps Aristea in $70M inflammation deal, secures buyout option
30. Rallybio down shifts to $81M IPO to fuel rare disease programs
31. Candel reels in downsized $72M IPO to get cancer-killing viruses through the clinic
32. IMIDomics emerges with $16.5M, former Takeda exec at the helm, and a precision approach to inflammatory disease
33. To turn off disease-causing genes, Talus Bio wants to knock proteins off of DNA
34. From speedy review to standstill: FDA spurns Iterum's antibiotic, demands another trial
35. Caribou grabs $304M IPO to herd off-the-shelf CAR-Ts into the clinic
36. Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table
37. Dicerna's RNA-silencing drug curbs harmful protein in rare liver disease
38. Lexeo snaps up Stelios, bolstering pipeline with trio of rare heart disease gene therapies
39. Turnstone Biologics rounds up $80M to fly cancer-killing virus, TIL treatment through the clinic
40. IAS: En route to FDA decision, Gilead's long-acting drug keeps HIV down in patients 'at the end of options'
41. Bayer's billion-dollar Parkinson's disease bet snags FDA fast-track tag
42. IAS: Merck's long-acting HIV med hits protective levels in phase 2
43. Don't forget to nominate 2021's fiercest women in life sciences
44. Merck oncology exec Haining pulls the trigger and goes full time at cell therapy player ArsenalBio
45. Tight-lipped no more, Erasca nabs $300M IPO to attack cancer's favorite pathway
46. Shape builds out RNA editing tech with a major $112M funding boost
47. New CEO, check. $172M round, check. Wugen's off-the-shelf cell therapies are ready for takeoff
48. Kriya grabs $100M to launch gene therapies into the mainstream, starting with diabetes
49. Prime Medicine uncloaks with $315M to push 'search and replace' gene editing treatments
50. Imago eyes $105M IPO to fuel blood cancer programs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.